Mylan/Biocon's Herceptin Biosimilar Phase III Data Published - Yahoo Sports

Submitted by Anonymous (not verified) on Wed, 12/28/2016 - 15:57

Sports PerspectivesMylan/Biocon's Herceptin Biosimilar Phase III Data PublishedYahoo Sports... Biocon Ltd. announced that data from a phase III HERITAGE study on their biosimilar version of Roche Holding AG's RHHBY cancer drug, Herceptin (trastuzumab), MYL-1401O, was published in the Journal of the American Medical Association (JAMA).Gilead Sciences, Inc. (NASDAQ:GILD) & Mylan NV (NASDAQ:MYL) Stocks in the SpotlightMoney Newsall 33 news articles »